S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How major US stock indexes fared Friday, 12/1/2023
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How major US stock indexes fared Friday, 12/1/2023
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How major US stock indexes fared Friday, 12/1/2023
US targets oil and natural gas industry's role in global warming with new rule on methane emissions
S&P 500   4,594.63
DOW   36,245.50
QQQ   389.94
Closing prices for crude oil, gold and other commodities
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
MarketBeat Week in Review – 11/27 - 12/1
Mega merger in the works? Humana, Cigna explore big deal
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Teen girls are being victimized by deepfake nudes. One family is pushing for more protections
Chicago and other northern US cities scramble to house migrants with coldest weather just ahead
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
How major US stock indexes fared Friday, 12/1/2023
US targets oil and natural gas industry's role in global warming with new rule on methane emissions

Novartis (NVS) Stock Forecast & Price Target

$98.13
+0.23 (+0.23%)
(As of 12/1/2023 ET)
Compare
Today's Range
$97.55
$98.32
50-Day Range
$92.29
$102.33
52-Week Range
$79.98
$105.61
Volume
1.20 million shs
Average Volume
1.32 million shs
Market Capitalization
$208.00 billion
P/E Ratio
26.38
Dividend Yield
2.31%
Price Target
$85.00

Novartis Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Hold
Based on 7 Analyst Ratings

Analysts' Consensus Price Target

$85.00
-13.38% Downside
High Forecast$85.00
Average Forecast$85.00
Low Forecast$85.00
TypeCurrent Forecast
12/2/22 to 12/2/23
1 Month Ago
11/2/22 to 11/2/23
3 Months Ago
9/3/22 to 9/3/23
1 Year Ago
12/2/21 to 12/2/22
Consensus Rating
Hold
Hold
Hold
Reduce
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
3 Buy rating(s)
4 Buy rating(s)
2 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
5 Hold rating(s)
10 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
2 Sell rating(s)
3 Sell rating(s)
Consensus Price Target$85.00$85.00$85.00$85.00
Predicted Upside-13.38% Downside-10.79% Downside-1.92% Downside6.12% Upside
Get Novartis Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for NVS and its competitors with MarketBeat's FREE daily newsletter.


NVS Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

NVS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Novartis Stock vs. The Competition

TypeNovartisMedical CompaniesS&P 500
Consensus Rating Score
2.43
2.67
2.49
Consensus RatingHoldModerate BuyHold
Predicted Upside-13.38% Downside646.65% Upside2,853.20% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/25/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Equal Weight
7/14/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy
4/26/2023Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
4/19/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$75.00 ➝ $85.00-13.28%
1/26/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Neutral
1/3/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderweight ➝ Neutral
12/14/2022UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ NeutralCHF 82 ➝ CHF 84
12/5/2022Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeHold ➝ Buy
(Data available from 12/2/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












NVS Price Target - Frequently Asked Questions

What is Novartis's consensus rating and price target?

According to the issued ratings of 7 analysts in the last year, the consensus rating for Novartis stock is Hold based on the current 4 hold ratings and 3 buy ratings for NVS. The average twelve-month price prediction for Novartis is $85.00 with a high price target of $85.00 and a low price target of $85.00. Learn more on NVS's analyst rating history.

Do Wall Street analysts like Novartis more than its competitors?

Analysts like Novartis less than other Medical companies. The consensus rating for Novartis is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how NVS compares to other companies.

Is Novartis being upgraded by Wall Street analysts?

Over the previous 90 days, Novartis's stock had 1 upgrade by analysts.

Does Novartis's stock price have much downside?

According to analysts, Novartis's stock has a predicted downside of -10.79% based on their 12-month stock forecasts.

What analysts cover Novartis?

Novartis has been rated by Morgan Stanley in the past 90 days.


Stock Ratings Reports and Tools

This page (NYSE:NVS) was last updated on 12/2/2023 by MarketBeat.com Staff

My Account -